Carlos Alban - Net Worth and Insider Trading

Carlos Alban Net Worth

The estimated net worth of Carlos Alban is at least $39 Million dollars as of 2024-04-23. Carlos Alban is the Vice Chairman of AbbVie Inc and owns about 155,341 shares of AbbVie Inc (ABBV) stock worth over $26 Million. Carlos Alban is also the Senior Vice President of Abbott Laboratories and owns about 114,817 shares of Abbott Laboratories (ABT) stock worth over $12 Million. Details can be seen in Carlos Alban's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Carlos Alban has not made any transactions after 2020-11-16 and currently still holds the listed stock(s).

Transaction Summary of Carlos Alban

Carlos Alban Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Carlos Alban owns 3 companies in total, including AbbVie Inc (ABBV) , Abbott Laboratories (ABT) , and SpringWorks Therapeutics Inc (SWTX) .

Click here to see the complete history of Carlos Alban’s form 4 insider trades.

Insider Ownership Summary of Carlos Alban

Ticker	Comapny	Transaction Date	Type of Owner
ABBV	AbbVie Inc	2020-11-16	EVP & Commercial Operations
ABT	Abbott Laboratories	2012-09-25	Senior Vice President
SWTX	SpringWorks Therapeutics Inc	2022-07-14	director

Carlos Alban Latest Holdings Summary

Carlos Alban currently owns a total of 2 stocks. Among these stocks, Carlos Alban owns 155,341 shares of AbbVie Inc (ABBV) as of November 16, 2020, with a value of $26 Million and a weighting of 68.07%. Carlos Alban also owns 114,817 shares of Abbott Laboratories (ABT) as of September 25, 2012, with a value of $12 Million and a weighting of 31.93%.

Latest Holdings of Carlos Alban

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ABBV	AbbVie Inc	2020-11-16	155,341	169.66	26,355,154
ABT	Abbott Laboratories	2012-09-25	114,817	107.69	12,364,643

Holding Weightings of Carlos Alban

Carlos Alban Form 4 Trading Tracker

According to the SEC Form 4 filings, Carlos Alban has made a total of 2 transactions in AbbVie Inc (ABBV) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in AbbVie Inc is the sale of 115,830 shares on November 16, 2020, which brought Carlos Alban around $12 Million.

According to the SEC Form 4 filings, Carlos Alban has made a total of 0 transactions in Abbott Laboratories (ABT) over the past 5 years. The most-recent trade in Abbott Laboratories is the sale of 1,198 shares on September 25, 2012, which brought Carlos Alban around $83,860.

Insider Trading History of Carlos Alban

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Carlos Alban Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Carlos Alban Ownership Network

Ownership Network List of Carlos Alban

No Data

Ownership Network Relation of Carlos Alban

Carlos Alban Owned Company Details

What does AbbVie Inc do?

Who are the key executives at AbbVie Inc?

Carlos Alban is the EVP & Commercial Operations of AbbVie Inc. Other key executives at AbbVie Inc include SVP & Enterprise Innovation Nicholas Donoghoe , SVP & US Commercial Operations Jeffrey Ryan Stewart , and EVP & Chief HR Officer Timothy J. Richmond .

AbbVie Inc (ABBV) Insider Trades Summary

Over the past 18 months, Carlos Alban made no insider transaction in AbbVie Inc (ABBV). Other recent insider transactions involving AbbVie Inc (ABBV) include a net sale of 58,955 shares made by Elaine K. Sorg , a net sale of 46,663 shares made by Perry C Siatis , and a net sale of 114,860 shares made by Azita Saleki-gerhardt .

In summary, during the past 3 months, insiders sold 459,004 shares of AbbVie Inc (ABBV) in total and bought 0 shares, with a net sale of 459,004 shares. During the past 18 months, 840,580 shares of AbbVie Inc (ABBV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 840,580 shares.

AbbVie Inc (ABBV)'s detailed insider trading history can be found in Insider Trading Tracker table.

AbbVie Inc Insider Transactions

No Available Data

What does Abbott Laboratories do?

Who are the key executives at Abbott Laboratories?

Carlos Alban is the Senior Vice President of Abbott Laboratories. Other key executives at Abbott Laboratories include VICE PRESIDENT Mccoy John A. Jr. , Executive Vice President Lisa D Earnhardt , and EXECUTIVE VICE PRESIDENT Louis H. Morrone .

Abbott Laboratories (ABT) Insider Trades Summary

Over the past 18 months, Carlos Alban made no insider transaction in Abbott Laboratories (ABT). Other recent insider transactions involving Abbott Laboratories (ABT) include a net sale of 89,305 shares made by Andrea F Wainer , a net sale of 200,000 shares made by Daniel J Starks , and a net sale of 11,943 shares made by John F Ginascol .

In summary, during the past 3 months, insiders sold 59,459 shares of Abbott Laboratories (ABT) in total and bought 0 shares, with a net sale of 59,459 shares. During the past 18 months, 329,865 shares of Abbott Laboratories (ABT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 329,865 shares.

Abbott Laboratories (ABT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Abbott Laboratories Insider Transactions

No Available Data

What does SpringWorks Therapeutics Inc do?

Who are the key executives at SpringWorks Therapeutics Inc?

Carlos Alban is the director of SpringWorks Therapeutics Inc. Other key executives at SpringWorks Therapeutics Inc include Chief People Officer Daniel Pichl , Chief Commercial Officer Bhavesh Ashar , and Chief Scientific Officer Tai-an Lin .

SpringWorks Therapeutics Inc (SWTX) Insider Trades Summary

Over the past 18 months, Carlos Alban made no insider transaction in SpringWorks Therapeutics Inc (SWTX). Other recent insider transactions involving SpringWorks Therapeutics Inc (SWTX) include a net sale of 42,039 shares made by Daniel Pichl , a net sale of 4,818 shares made by Julie Hambleton , and a net sale of 1,750,000 shares made by Jeffrey Lawrence Schwartz .

In summary, during the past 3 months, insiders sold 49,237 shares of SpringWorks Therapeutics Inc (SWTX) in total and bought 0 shares, with a net sale of 49,237 shares. During the past 18 months, 1,804,913 shares of SpringWorks Therapeutics Inc (SWTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,804,913 shares.

SpringWorks Therapeutics Inc (SWTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

SpringWorks Therapeutics Inc Insider Transactions

No Available Data

Carlos Alban Mailing Address

Above is the net worth, insider trading, and ownership report for Carlos Alban. You might contact Carlos Alban via mailing address: 1 N. Waukegan Road, North Chicago Il 60064.

Discussions on Carlos Alban

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Data is updated daily.